Authors

• Siddhesh Kamat (ORCID: https://orcid.org/0000-0001-5205-9184)
• Wytske J. Fokkens (ORCID: https://orcid.org/0000-0003-4852-229X)
• Juby A. Jacob‐Nara (ORCID: https://orcid.org/0000-0002-5372-8762)
• Jérôme Msihid (ORCID: https://orcid.org/0000-0003-4733-5855)
• Kinga Borsos
• Claus Bachert (ORCID: https://orcid.org/0000-0003-4742-1665)
• Scott Nash (ORCID: https://orcid.org/0000-0001-9208-5280)
• Leda Mannent
• Claire Hopkins (ORCID: https://orcid.org/0000-0003-3993-1569)
• Asif Khan (ORCID: https://orcid.org/0000-0001-9158-0116)
• Paul J. Rowe
• Harry Sacks
• Joseph K. Han
• Yamo Deniz

Institutions

• Eastern Virginia Medical School (US)
• King's College London (GB)
• Regeneron (United States) (US)
• Sanofi (France) (FR)
• Sanofi (United States) (US)
• Amsterdam University Medical Centers (NL)

Publication Details

Journal

Annals of Allergy Asthma & Immunology

Published

2024-09-28

DOI

https://doi.org/10.1016/j.anai.2024.09.015

Citations

2

Primary Topic

Sinusitis and nasal conditions

Type

article

Field-Weighted Citation Impact

1.16

Funders

• GlaxoSmithKline
• Sanofi
• Regeneron Pharmaceuticals
• Mylan